Findings of Research Misconduct, 35546 [2014-14627]

Download as PDF 35546 Federal Register / Vol. 79, No. 120 / Monday, June 23, 2014 / Notices Scholar in Residence in the Health Sector Management Program at Duke University’s Fuqua School of Business, and William J. Hall, MD, Director of the Center for Healthy Aging at the University of Rochester School of Medicine. In addition, Commissioner Jon B. Christianson, Ph.D., Professor in the Division of Health Policy and Management at the School of Public Health at the University of Minnesota in Minneapolis has been designated as Vice Chair of the Commission. [42 U.S.C. 1395b–6.] Gene L. Dodaro, Comptroller General of the United States. [FR Doc. 2014–14500 Filed 6–20–14; 8:45 am] BILLING CODE 1610–02–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Melanie Cokonis, Southern Research Institute: Based on the report of an investigation conducted by Southern Research Institute (SRI) and additional analysis conducted by ORI in its oversight review, ORI found that Ms. Melanie Cokonis, former Research Technician, SRI, engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), contracts N01–AI–30047 (HHSN2722011000009C) and N01–AI– 70042 (HHSN272200700042C), and National Human Genome Research Institute (NHGRI), NIH, grant U54 HG005034. ORI found that the Respondent engaged in research misconduct by falsifying assay data that were submitted in reports to NIH. Specifically, ORI found that Respondent knowingly falsified data for cytoprotection assays with antiviral compounds and provided the false data for inclusion in reports submitted to NIH for contracts N01–AI– 30047 and N01–AI–70042 and grant U54 HG005034. Respondent transferred raw data from 8X12 SoftmaxPro matrix files into spreadsheets and then falsified the numbers for cell control, virus control, drug cytotoxicity, drug only, and/or cells+ virus+ drug wells to make emcdonald on DSK67QTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:33 Jun 20, 2014 Jkt 232001 206 assays appear to have been successfully performed when they were not. Ms. Cokonis has voluntarily agreed for a period of three (3) years, beginning on May 29, 2014: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); and (2) To exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8800. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2014–14627 Filed 6–20–14; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women, Centers for Disease Control and Prevention: Notice of Charter Renewal This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the Advisory Committee on Breast Cancer in Young Women, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), has been renewed for a 2-year period through June 17, 2016. For information, contact Temeika L. Fairley, Ph.D., Designated Federal Officer, Advisory Committee on Breast Cancer in Young Women, HHS, CDC, 4770 Buford Highway NE., Mailstop K52, Atlanta, Georgia 30341, telephone 770/488–4518, fax 770/488–4760. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 Prevention and the Agency for Toxic Substances and Disease Registry. Gary J. Johnson, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2014–14616 Filed 6–20–14; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee (HICPAC) In accordance with section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting for the aforementioned committee: Times and Dates: 9:00 a.m.–5:00 p.m., July 17, 2014 9:00 a.m.–12:00 p.m., July 18, 2014 Place: CDC, Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road, Atlanta, Georgia, 30333 Status: Open to the public, limited only by the space available. Please register for the meeting at www.cdc.gov/hicpac. Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, the Secretary, Department of Health and Human Services regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions. Matters for Discussion: The agenda will include updates on the Draft Guideline to Prevent Surgical Site Infections; the Draft Guideline to Prevent Infections in Neonatal Intensive Care Units; CDC’s activities for prevention of antimicrobial resistant healthcare associated infections; updates on prevention and surveillance of catheterassociated urinary tract infections; and HICPAC core infection prevention and control practices. Agenda items are subject to change as priorities dictate. Contact Person For More Information: Erin Stone, M.S., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE., Mailstop A–07, Atlanta, Georgia 30333, Telephone: (404) 639–4045, Email: hicpac@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices E:\FR\FM\23JNN1.SGM 23JNN1

Agencies

[Federal Register Volume 79, Number 120 (Monday, June 23, 2014)]
[Notices]
[Page 35546]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-14627]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY:  Office of the Secretary, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Melanie Cokonis, Southern Research Institute: Based on the report 
of an investigation conducted by Southern Research Institute (SRI) and 
additional analysis conducted by ORI in its oversight review, ORI found 
that Ms. Melanie Cokonis, former Research Technician, SRI, engaged in 
research misconduct in research supported by National Institute of 
Allergy and Infectious Diseases (NIAID), National Institutes of Health 
(NIH), contracts N01-AI-30047 (HHSN2722011000009C) and N01-AI-70042 
(HHSN272200700042C), and National Human Genome Research Institute 
(NHGRI), NIH, grant U54 HG005034.
    ORI found that the Respondent engaged in research misconduct by 
falsifying assay data that were submitted in reports to NIH. 
Specifically, ORI found that Respondent knowingly falsified data for 
cytoprotection assays with antiviral compounds and provided the false 
data for inclusion in reports submitted to NIH for contracts N01-AI-
30047 and N01-AI-70042 and grant U54 HG005034. Respondent transferred 
raw data from 8X12 SoftmaxPro matrix files into spreadsheets and then 
falsified the numbers for cell control, virus control, drug 
cytotoxicity, drug only, and/or cells+ virus+ drug wells to make 206 
assays appear to have been successfully performed when they were not.
    Ms. Cokonis has voluntarily agreed for a period of three (3) years, 
beginning on May 29, 2014:
    (1) To exclude herself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide 
Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment 
Regulations''); and
    (2) To exclude herself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8800.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-14627 Filed 6-20-14; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.